Management and outcomes of histoplasmosis in youth with inflammatory bowel disease in an endemic area.

ABSTRACT:

Objective

Patients with inflammatory bowel disease (IBD) prescribed immunosuppressive therapies including antitumor necrosis factor (aTNF) therapies are at increased risk of histoplasmosis. We aim to evaluate the presentation, management, and outcomes of youth with IBD and concurrent histoplasmosis.

Methods

Single center, retrospective review of youth with IBD diagnosed with histoplasmosis from January 12, 2007 to January 1, 2022. Management and outcomes were followed for up to 2 years after diagnosis.

Results

Nineteen patients (10 male, median age 16 years, range 8-22) with IBD were diagnosed with histoplasmosis: disseminated (N = 15/19; 79%), pulmonary (N = 3/19; 16%), lymph node (N = 1/19; 5%). At the time of histoplasmosis diagnosis, patients were predominantly re

SUBMITTER: Wright JC 

PROVIDER: S-EPMC11615130 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature